BE2014C016I2 - - Google Patents

Download PDF

Info

Publication number
BE2014C016I2
BE2014C016I2 BE2014C016C BE2014C016C BE2014C016I2 BE 2014C016 I2 BE2014C016 I2 BE 2014C016I2 BE 2014C016 C BE2014C016 C BE 2014C016C BE 2014C016 C BE2014C016 C BE 2014C016C BE 2014C016 I2 BE2014C016 I2 BE 2014C016I2
Authority
BE
Belgium
Application number
BE2014C016C
Other languages
French (fr)
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32185709&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2014C016(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of BE2014C016I2 publication Critical patent/BE2014C016I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BE2014C016C 2002-11-15 2014-02-27 BE2014C016I2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10253282A DE10253282A1 (de) 2002-11-15 2002-11-15 Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung

Publications (1)

Publication Number Publication Date
BE2014C016I2 true BE2014C016I2 (pt) 2023-03-07

Family

ID=32185709

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2014C016C BE2014C016I2 (pt) 2002-11-15 2014-02-27

Country Status (38)

Country Link
EP (2) EP2025338A1 (pt)
JP (1) JP4317138B2 (pt)
KR (1) KR101092247B1 (pt)
CN (3) CN101817800A (pt)
AR (2) AR041969A1 (pt)
AT (1) ATE430569T1 (pt)
AU (1) AU2003285326B2 (pt)
BE (1) BE2014C016I2 (pt)
BR (1) BRPI0316264B8 (pt)
CA (1) CA2506082C (pt)
CO (1) CO5570670A2 (pt)
CY (2) CY1110500T1 (pt)
DE (2) DE10253282A1 (pt)
DK (1) DK1562603T3 (pt)
EA (1) EA008665B1 (pt)
EC (1) ECSP055774A (pt)
ES (1) ES2326878T7 (pt)
FR (1) FR14C0049I2 (pt)
HR (1) HRP20050432B1 (pt)
HU (1) HUS1400011I1 (pt)
IL (1) IL167900A (pt)
LT (1) LTC1562603I2 (pt)
LU (1) LU92433I2 (pt)
ME (1) ME00354B (pt)
MX (1) MXPA05005081A (pt)
MY (1) MY136034A (pt)
NL (1) NL300650I2 (pt)
NO (2) NO334314B1 (pt)
NZ (1) NZ540661A (pt)
PE (1) PE20040694A1 (pt)
PL (1) PL212238B1 (pt)
PT (1) PT1562603E (pt)
RS (1) RS51607B (pt)
SI (1) SI1562603T1 (pt)
TW (1) TWI343812B (pt)
UA (1) UA81276C2 (pt)
WO (1) WO2004045618A2 (pt)
ZA (1) ZA200502246B (pt)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
ATE539754T1 (de) 2004-04-22 2012-01-15 Boehringer Ingelheim Int Arzneinmittelkombinationen enthaltend benzoxazine zur behandlung von atemwegserkrankungen
DE102004019539A1 (de) * 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von Atemwegserkrankungen
WO2005110990A1 (de) * 2004-05-13 2005-11-24 Boehringer Ingelheim International Gmbh Hydroxy-substituierte benzkondensierte heterozyklen als betaagonisten zur behandlung von atemwegserkrankungen
US20050256115A1 (en) * 2004-05-14 2005-11-17 Boehringer Ingelheim International Gmbh Aerosol formulation for the inhalation of beta-agonists
US7745621B2 (en) 2004-05-14 2010-06-29 Boehringer Ingelheim International Gmbh Long acting bronchodilators for the treatment of respiratory diseases
US7220742B2 (en) 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
DE102004024451A1 (de) * 2004-05-14 2005-12-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierungen für die Inhalation, die Enantiomerenreine Betaagonisten enthalten
DE102004024453A1 (de) * 2004-05-14 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Bronchodilatoren zur Behandlung von Atemwegserkrankungen
DE102004024452A1 (de) * 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosolformulierung für die Inhalation von Betaagonisten
DE102004024454A1 (de) * 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Enantiomerenreine Betaagonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
DE102004045648A1 (de) * 2004-09-21 2006-03-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Betamimetika zur Behandlung von Atemwegserkrankungen
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
DE102005007654A1 (de) * 2005-02-19 2006-08-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
DE102005030733A1 (de) * 2005-07-01 2007-01-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen enthaltend langwirksame Beta-2-Agonisten und wenigstens einen weiteren Wirkstoff
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
EP1924553A1 (en) 2005-08-08 2008-05-28 Argenta Discovery Limited Bicyclo[2.2.]hept-7-ylamine derivatives and their uses
ES2530991T3 (es) 2005-08-15 2015-03-09 Boehringer Ingelheim Int Procedimiento para la obtención de betamiméticos
US20070088030A1 (en) * 2005-10-10 2007-04-19 Barbara Niklaus-Humke Aerosol formulations for the inhalation of beta-agonists
TWI396541B (zh) * 2005-10-10 2013-05-21 Boehringer Ingelheim Int 用於治療呼吸疾病之新穎藥物組合
EP2532677A1 (en) 2005-10-21 2012-12-12 Novartis AG Human antibodies against il13 and therapeutic uses
AU2006311060A1 (en) * 2005-11-09 2007-05-18 Boehringer Ingelheim International Gmbh Aerosolformulation for inhalation
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
JP2009526817A (ja) * 2006-02-16 2009-07-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器疾患の治療用医薬組成物
PE20080142A1 (es) * 2006-03-15 2008-04-14 Boehringer Ingelheim Int Beta-agonistas enantiomericamente puros y sus procedimientos de preparacion
PL2322525T3 (pl) 2006-04-21 2014-03-31 Novartis Ag Pochodne puryny do zastosowania jako agoniści receptora adenozyny A<sub>2A</sub>
WO2008017638A1 (de) * 2006-08-07 2008-02-14 Boehringer Ingelheim International Gmbh Enantiomerenreine betaagonisten, verfahren zu deren herstellung und deren verwendung als arzneimittel
UY30542A1 (es) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de agonistas beta
UY30543A1 (es) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de beta- agonistas
BRPI0717564A2 (pt) 2006-09-29 2013-10-22 Novartis Ag Pirazolopirimidinas como inibidores de pi3k lipídeo cinase
CA2667962A1 (en) 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
RS51644B (en) 2007-01-10 2011-10-31 Irm Llc. UNITS AND PREPARATIONS AS CHANNEL INHIBITORS ACTIVATING PROSTHESES
DK2125759T3 (da) * 2007-01-25 2011-09-19 Boehringer Ingelheim Int Fremgangsmåde til fremstilling af betamimetika
PL2155721T3 (pl) 2007-05-07 2011-07-29 Novartis Ag Związki organiczne
PT2444120T (pt) 2007-12-10 2018-01-03 Novartis Ag Análogos da amilorida espirocíclicos como bloqueadores de enac
KR20100113557A (ko) 2008-01-11 2010-10-21 노파르티스 아게 키나제 억제제로서의 피리미딘
AU2009256645A1 (en) 2008-06-10 2009-12-17 Novartis Ag Pyrazine derivatives as epithelial sodium channel blockers
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
PT2379507E (pt) 2008-12-30 2014-01-21 Pulmagen Therapeutics Inflammation Ltd Compostos de sulfonamida para o tratamento de desordens respiratórias
ES2396023T3 (es) 2009-01-29 2013-02-18 Novartis Ag Bencimidazoles sustituidos para el tratamiento de astrocitomas
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
JP5781510B2 (ja) 2009-08-12 2015-09-24 ノバルティス アーゲー ヘテロ環式ヒドラゾン化合物および癌および炎症の処置のためのそれらの使用
JP5819831B2 (ja) 2009-08-17 2015-11-24 インテリカイン， エルエルシー 複素環式化合物およびそれらの使用
EP2813227A1 (en) 2009-10-22 2014-12-17 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
WO2011098746A1 (en) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
WO2012040082A2 (en) * 2010-09-21 2012-03-29 Intekrin Therapeutics, Inc. Antidiabetic solid pharmaceutical compositions
JP2014505088A (ja) 2011-02-10 2014-02-27 ノバルティス アーゲー Ｃ−ＭＥＴチロシンキナーゼ阻害剤としての［１，２，４］トリアゾロ［４，３−ｂ］ピリダジン化合物
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
US9102671B2 (en) 2011-02-25 2015-08-11 Novartis Ag Compounds and compositions as TRK inhibitors
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
JP5957526B2 (ja) 2011-09-15 2016-07-27 ノバルティス アーゲー チロシンキナーゼとしての６−置換３−（キノリン−６−イルチオ）−［１，２，４］トリアゾロ［４，３−ａ］ピラジン
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
EP2755652B1 (en) 2011-09-16 2021-06-02 Novartis AG N-substituted heterocyclyl carboxamides
ES2558457T3 (es) 2011-09-16 2016-02-04 Novartis Ag Compuestos heterocíclicos para el tratamiento de fibrosis quística
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
EP2793893A4 (en) 2011-11-23 2015-07-08 Intellikine Llc IMPROVED TREATMENT REGIMES USING MTOR INHIBITORS
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
EP3964513A1 (en) 2012-04-03 2022-03-09 Novartis AG Combination products with tyrosine kinase inhibitors and their use
WO2014056840A1 (en) 2012-10-09 2014-04-17 Boehringer Ingelheim International Gmbh Beta-2-adrenoceptor agonist for the treatment of cough
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
CN105246482A (zh) 2013-03-15 2016-01-13 因特利凯有限责任公司 激酶抑制剂的组合及其用途
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
KR20160141856A (ko) 2014-04-24 2016-12-09 노파르티스 아게 포스파티딜이노시톨 3-키나제 억제제로서의 피라진 유도체
CN106458979B (zh) 2014-04-24 2020-03-27 诺华股份有限公司 作为磷脂酰肌醇3-激酶抑制剂的氨基吡嗪衍生物
PT3134396T (pt) 2014-04-24 2019-12-16 Novartis Ag Derivados de amino piridina como inibidores da fosfatidilinositol 3-quinase
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
US10195208B2 (en) 2014-07-31 2019-02-05 Novartis Ag Combination therapy
EP3551187B1 (en) 2016-12-12 2021-02-17 Boehringer Ingelheim International GmbH Nintedanib for use in methods for the treatment of interstitial lung diseases by coadministration with olodaterol
HRP20211915T1 (hr) 2016-12-20 2022-03-18 Inke, S.A. Poboljšani postupak dobivanja r-6-hidroksi-8-[1-hidroksi-2-[2-(4-metoksifenil)-1,1-dimetiletilaminoetil]-2h-1,4-benzoksazin-3(4h)-on-hidroklorida
CN108997248B (zh) * 2018-08-06 2023-08-01 上海方予健康医药科技有限公司 盐酸奥达特罗晶型b及其制备方法
CN109096218B (zh) * 2018-08-06 2020-10-27 上海方予健康医药科技有限公司 盐酸奥达特罗晶型a及其制备方法
WO2020250116A1 (en) 2019-06-10 2020-12-17 Novartis Ag Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis
JOP20220044A1 (ar) 2019-08-28 2023-01-30 Novartis Ag مشتقات 1، 3- فينيل أريل غير متجانسة بها استبدال واستخدامها في معالجة مرض
CN115768404A (zh) * 2020-06-09 2023-03-07 广州谷森制药有限公司 含乌美溴铵和三苯乙酸维兰特罗的药物制剂
US11331322B1 (en) 2021-09-15 2022-05-17 Santen Pharmaceutical Co., Ltd. Medicament for preventing and/or treating dry eye

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3134590A1 (de) * 1981-09-01 1983-03-10 Boehringer Ingelheim KG, 6507 Ingelheim Neue benzo-heterocyclen
US4460581A (en) * 1982-10-12 1984-07-17 Boehringer Ingelheim Kg (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones
DE3743265A1 (de) * 1987-12-19 1989-06-29 Boehringer Ingelheim Kg Neue ammoniumverbindungen, ihre herstellung und verwendung
IL152140A0 (en) * 2000-04-27 2003-05-29 Boehringer Ingelheim Pharma Novel, slow-acting betamimetics, a method for their production and their use as medicaments

Also Published As

Publication number Publication date
ES2326878T7 (es) 2014-03-11
CY2014032I2 (el) 2015-12-09
BRPI0316264B1 (pt) 2019-04-09
CN101735166A (zh) 2010-06-16
RS20050361A (en) 2007-04-10
EP1562603B1 (de) 2009-05-06
CN101817800A (zh) 2010-09-01
AU2003285326B2 (en) 2009-06-04
ES2326878T3 (es) 2009-10-21
EP1562603B3 (de) 2014-01-08
HUS1400011I1 (hu) 2022-02-28
PT1562603E (pt) 2009-06-18
FR14C0049I1 (pt) 2014-08-08
UA81276C2 (en) 2007-12-25
CO5570670A2 (es) 2005-10-31
IL167900A (en) 2013-06-27
MXPA05005081A (es) 2005-07-01
DK1562603T3 (da) 2009-09-07
EA200500715A1 (ru) 2005-12-29
MY136034A (en) 2008-07-31
ECSP055774A (es) 2005-11-22
NO20052883L (no) 2005-06-14
FR14C0049I2 (fr) 2015-07-24
RS51607B (sr) 2011-08-31
CY1110500T1 (el) 2015-04-29
EA008665B1 (ru) 2007-06-29
MEP53608A (en) 2011-05-10
EP2025338A1 (de) 2009-02-18
KR20050075013A (ko) 2005-07-19
LU92433I2 (fr) 2014-06-24
BR0316264A (pt) 2005-10-11
JP2006508140A (ja) 2006-03-09
WO2004045618A2 (de) 2004-06-03
CA2506082C (en) 2011-06-21
SI1562603T1 (sl) 2009-10-31
NO334314B1 (no) 2014-02-03
KR101092247B1 (ko) 2011-12-12
WO2004045618A3 (de) 2004-09-30
CY2014032I1 (el) 2015-12-09
PL375270A1 (en) 2005-11-28
PE20040694A1 (es) 2004-11-23
NZ540661A (en) 2007-12-21
ME00354B (me) 2011-10-10
DE50311502D1 (de) 2009-06-18
TWI343812B (en) 2011-06-21
CN1713914A (zh) 2005-12-28
DE10253282A1 (de) 2004-05-27
NL300650I2 (nl) 2017-11-02
HRP20050432B1 (en) 2012-01-31
ZA200502246B (en) 2006-01-25
HRP20050432A2 (en) 2006-06-30
JP4317138B2 (ja) 2009-08-19
EP1562603A2 (de) 2005-08-17
CA2506082A1 (en) 2004-06-03
NO2014005I1 (no) 2014-03-10
AU2003285326A1 (en) 2004-06-15
LTC1562603I2 (lt) 2016-12-12
AR041969A1 (es) 2005-06-01
BRPI0316264B8 (pt) 2021-05-25
ATE430569T1 (de) 2009-05-15
AR087241A2 (es) 2014-03-12
PL212238B1 (pl) 2012-08-31
TW200423943A (en) 2004-11-16

Similar Documents

Publication Publication Date Title
BE2019C547I2 (pt)
BE2019C510I2 (pt)
BE2018C021I2 (pt)
BE2017C049I2 (pt)
BE2017C005I2 (pt)
BE2016C069I2 (pt)
BE2016C040I2 (pt)
BE2018C018I2 (pt)
FR14C0049I1 (pt)
BE2014C015I2 (pt)
BE2013C063I2 (pt)
BE2013C039I2 (pt)
BE2013C025I2 (pt)
BE2011C038I2 (pt)
JP2003122509A5 (pt)
JP2003116134A5 (pt)
BRPI0302144B1 (pt)
BRPI0215435A2 (pt)
BE2013C046I2 (pt)
JP2002273889A5 (pt)
JP2002339240A5 (pt)
JP2003222006A5 (pt)
JP2003210823A5 (pt)
JP2003220270A5 (pt)
BR0315835A2 (pt)